MicroRNAs in liver disease: From diagnostics to therapeutics

Clinical Biochemistry

Volumn 46, Issue 10-11, 2013, Pages 946-952

  Takahashi, Kenji ^a   Yan, Irene ^a   Wen, Hui Ju ^a   Patel, Tushar ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hepatitis; Hepatobiliary diseases; Hepatocellular cancer; Non coding RNA

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; FARNESOID X RECEPTOR; FLUOROURACIL; GELATINASE A; HISTONE DEACETYLASE 4; MICRORNA; MICRORNA 122; MICRORNA 135A; MICRORNA 146A; MICRORNA 148A; MICRORNA 155; MICRORNA 16; MICRORNA 192; MICRORNA 200A; MICRORNA 200B; MICRORNA 21; MICRORNA 22; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 29; MICRORNA 34A; PROTEIN BCL 2; PROTEIN MCL 1; RNA INDUCED SILENCING COMPLEX; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; APOPTOSIS; BILE DUCT ATRESIA; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CLINICAL EXAMINATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OPTIMISM; POLYADENYLATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; STANDARDIZATION; TOXIC HEPATITIS; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; RNA, NEOPLASM;

EID: 84886090197     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.01.025     Document Type: Review

References (85)

1. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
2. Sayed D., Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011, 91:827-887.
3. Shukla G.C., Singh J., Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol 2011, 3:83-92.
4. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9:775-789.
5. Borchert G.M., Lanier W., Davidson B.L. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006, 13:1097-1101.
6. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H., et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004, 23:4051-4060.
7. Han J., Lee Y., Yeom K.H., Kim Y.K., Jin H., Kim V.N. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004, 18:3016-3027.
8. Landthaler M., Yalcin A., Tuschl T. The human digeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004, 14:2162-2167.
9. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., et al. The nuclear RNAse III Drosha initiates microRNA processing. Nature 2003, 425:415-419.
10. Bohnsack M.T., Czaplinski K., Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004, 10:185-191.
11. Hammond S.M., Bernstein E., Beach D., Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000, 404:293-296.
12. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
13. Kunej T., Godnic I., Ferdin J., Horvat S., Dovc P., Calin G.A. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res 2011, 717:77-84.
14. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
15. Fang J.H., Zhou H.C., Zeng C., Yang J., Liu Y., Huang X., et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011, 54:1729-1740.
16. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
17. Pineau P., Volinia S., McJunkin K., Marchio A., Battiston C., Terris B., et al. Mir-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010, 107:264-269.
18. Quintavalle C., Garofalo M., Zanca C., Romano G., Iaboni M., del Basso De Caro M., et al. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 2012, 31:858-868.
19. Haybaeck J., Zeller N., Heikenwalder M. The parallel universe: microRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis. Swiss Med Wkly 2011, 141:w13287.
20. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
21. Tomimaru Y., Eguchi H., Nagano H., Wada H., Tomokuni A., Kobayashi S., et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010, 103:1617-1626.
22. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog in press. http://dx.doi.org/10.1002/mc.21864.
23. Tomimaru Y., Eguchi H., Nagano H., Wada H., Kobayashi S., Marubashi S., et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012, 56:167-175.
24. Li W., Xie L., He X., Li J., Tu K., Wei L., et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008, 123:1616-1622.
25. Park J.K., Kogure T., Nuovo G.J., Jiang J., He L., Kim J.H., et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011, 71:7608-7616.
26. Ding J., Huang S., Wu S., Zhao Y., Liang L., Yan M., et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol 2010, 12:390-399.
27. Liu S., Guo W., Shi J., Li N., Yu X., Xue J., et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 2012, 56:389-396.
28. Xu T., Zhu Y., Wei Q.K., Yuan Y., Zhou F., Ge Y.Y., et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 2008, 29:2126-2131.
29. Fabbri M., Garzon R., Cimmino A., Liu Z., Zanesi N., Callegari E., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3a and 3b. Proc Natl Acad Sci U S A 2007, 104:15805-15810.
30. Wang C.M., Wang Y., Fan C.G., Xu F.F., Sun W.S., Liu Y.G., et al. miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 2011, 411:586-592.
31. Pandey D.P., Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 2009, 29:3783-3790.
32. Xiong J., Yu D., Wei N., Fu H., Cai T., Huang Y., et al. An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 2010, 277:1684-1694.
33. Zhang J., Yang Y., Yang T., Liu Y., Li A., Fu S., et al. MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010, 103:1215-1220.
34. Ji J., Zhao L., Budhu A., Forgues M., Jia H.L., Qin L.X., et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 2010, 52:690-697.
35. Webster R.J., Giles K.M., Price K.J., Zhang P.M., Mattick J.S., Leedman P.J. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009, 284:5731-5741.
36. Fang Y.X., Xue J.L., Shen Q., Chen J., Tian L. miR-7 inhibits tumor growth and metastasis by targeting the PI3K/Akt pathway in hepatocellular carcinoma. Hepatology 2012, 55(6):1852-1862.
37. Zhou J., Yu L., Gao X., Hu J., Wang J., Dai Z., et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011, 29:4781-4788.
38. Qi P., Cheng S.Q., Wang H., Li N., Chen Y.F., Gao C.F. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011, 6:e28486.
39. Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.G., et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007, 67:6092-6099.
40. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006, 3:33-42.
41. Meng F., Henson R., Lang M., Wehbe H., Maheshwari S., Mendell J.T., et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129.
42. He Q, Cai L, Shuai L, Li D, Wang C, Liu Y, et al. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog in press. http://dx.doi.org/10.1002/mc.21859.
43. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
44. Guo J., Miao Y., Xiao B., Huan R., Jiang Z., Meng D., et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 2009, 24:652-657.
45. Hao J., Zhang S., Zhou Y., Liu C., Hu X., Shao C. MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochem Biophys Res Commun 2011, 406:552-557.
46. Zhong X.Y., Yu J.H., Zhang W.G., Wang Z.D., Dong Q., Tai S., et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid×receptor expression. Gene 2012, 493:44-51.
47. Razumilava N., Bronk S.F., Smoot R.L., Fingas C.D., Werneburg N.W., Roberts L.R., et al. miR-25 targets TNF-related apoptosis inducing ligand (trail) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology 2012, 55:465-475.
48. Olaru A.V., Ghiaur G., Yamanaka S., Luvsanjav D., An F., Popescu I., et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/s checkpoint. Hepatology 2011, 54:2089-2098.
49. Meng F., Wehbe-Janek H., Henson R., Smith H., Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008, 27:378-386.
50. Chen Y., Gao W., Luo J., Tian R., Sun H., Zou S. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Oncol Rep 2011, 25:443-451.
51. Chen Y., Luo J., Tian R., Sun H., Zou S. miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci 2011, 56:1693-1701.
52. Palmer W.C., Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012, 57:69-76.
53. Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011, 50:136-142.
54. Zhang Y., Jia Y., Zheng R., Guo Y., Wang Y., Guo H., et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010, 56:1830-1838.
55. Chen Y., Shen A., Rider P.J., Yu Y., Wu K., Mu Y., et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 2011, 25:4511-4521.
56. Wong Q.W., Lung R.W., Law P.T., Lai P.B., Chan K.Y., To K.F., et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008, 135:257-269.
57. Bihrer V., Waidmann O., Friedrich-Rust M., Forestier N., Susser S., Haupenthal J., et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011, 6:e26971.
58. Marquez R.T., Bandyopadhyay S., Wendlandt E.B., Keck K., Hoffer B.A., Icardi M.S., et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010, 90:1727-1736.
59. Chang J., Nicolas E., Marks D., Sander C., Lerro A., Buendia M.A., et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004, 1:106-113.
60. Cermelli S., Ruggieri A., Marrero J.A., Ioannou G.N., Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011, 6:e23937.
61. Morita K., Taketomi A., Shirabe K., Umeda K., Kayashima H., Ninomiya M., et al. Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int 2011, 31:474-484.
62. Murakami Y., Aly H.H., Tajima A., Inoue I., Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009, 50:453-460.
63. Murakami Y., Toyoda H., Tanaka M., Kuroda M., Harada Y., Matsuda F., et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011, 6:e16081.
64. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
65. Abdalla M.A., Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer 2012, 3:19-31.
66. Ishida H., Tatsumi T., Hosui A., Nawa T., Kodama T., Shimizu S., et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 2011, 412:92-97.
67. Miranda R.C., Pietrzykowski A.Z., Tang Y., Sathyan P., Mayfield D., Keshavarzian A., et al. MicroRNAs: master regulators of ethanol abuse and toxicity?. Alcohol Clin Exp Res 2010, 34:575-587.
68. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963.
69. Bala S., Marcos M., Kodys K., Csak T., Catalano D., Mandrekar P., et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (tnf{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011, 286:1436-1444.
70. Yin H., Hu M., Zhang R., Shen Z., Flatow L., You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 2012, 287:9817-9826.
71. Hartley J.L., Davenport M., Kelly D.A. Biliary atresia. Lancet 2009, 374:1704-1713.
72. Hand N.J., Horner A.M., Master Z.R., Boateng L.A., LeGuen C., Uvaydova M., et al. MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia. J Pediatr Gastroenterol Nutr 2012, 54:186-192.
73. Zong Y., Stanger B.Z. Molecular mechanisms of bile duct development. Int J Biochem Cell Biol 2011, 43:257-264.
74. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48:1810-1820.
75. Jin X., Ye Y.F., Chen S.H., Yu C.H., Liu J., Li Y.M. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis 2009, 41:289-297.
76. Zheng L., Lv G.C., Sheng J., Yang Y.D. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol 2010, 25:156-163.
77. Farid W.R., Pan Q., van der Meer A.J., de Ruiter P.E., Ramakrishnaiah V., de Jonge J., et al. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 2012, 18:290-297.
78. Kogure T., Costinean S., Yan I., Braconi C., Croce C., Patel T. Hepatic miR-29ab1 expression modulates chronic hepatic injury. J Cell Mol Med 2012, 16(11):2647-2654.
79. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009, 106:4402-4407.
80. Song J., Bai Z., Han W., Zhang J., Meng H., Bi J., et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 2012, 57:897-904.
81. Sidorkiewicz M., Grek M., Jozwiak B., Majda-Stanislawska E., Piekarska A., Bartkowiak J. Expression of microRNA-155 precursor in peripheral blood mononuclear cells from hepatitis C patients after antiviral treatment. Acta Virol 2010, 54:75-78.
82. Tomokuni A., Eguchi H., Tomimaru Y., Wada H., Kawamoto K., Kobayashi S., et al. miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2011, 414:675-680.
83. Braconi C., Valeri N., Gasparini P., Huang N., Taccioli C., Nuovo G., et al. Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes. Clin Cancer Res 2010, 16:957-966.
84. Borel F., Han R., Visser A., Petry H., van Deventer S.J., Jansen P.L., et al. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012, 55:821-832.
85. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.